Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Gap Down - Should You Sell?

Key Points

• Sino Biopharmaceutical shares gapped down from a previous close of $1.16 to open at $1.06, resulting in an 8.5% decrease for the stock.
• The stock's 50-day simple moving average is $1.00, while the two-hundred day average stands at $0.70, indicating a potential bearish sentiment.
• Sino Biopharmaceutical operates as a research and development pharmaceutical conglomerate in China, offering various treatments, including oncology and liver disease medications.

Sino Biopharmaceutical (OTCMKTS:SBMFF - ) shares gapped down prior to trading on Wednesday . The stock had previously closed at $1.16, but opened at $1.06. Sino Biopharmaceutical shares last traded at $1.06, with a volume of 465 shares changing hands.

Sino Biopharmaceutical Stock Down 8.5%

The stock's 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $0.70.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.